Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Asian Pac J Cancer Prev ; 14(10): 5687-92, 2013.
Article in English | MEDLINE | ID: mdl-24289563

ABSTRACT

Type 2 diabetes mellitus (T2DM) has contributed to advanced breast cancer development over the past decades. However, the mechanism underlying this contribution is poorly understood. In this study, we determined that high glucose enhanced proteasome activity was accompanied by enhanced proliferation, migration and invasion, as well as suppressed apoptosis, in human breast cancer MCF-7 cells. Proteasome inhibitor bortezomib (BZM) pretreatment mitigated high glucose-induced MCF-7 cell growth and invasion. Furthermore, high glucose increased protein kinase C delta (PKC?)-phosphorylation. Administration of the specific PKC? inhibitor rottlerin attenuated high glucose-stimulated cancer cell growth and invasion. In addition, PKC? inhibition by both rottlerin and PKC? shRNA significantly suppressed high glucose-induced proteasome activity. Our results suggest that PKC?-dependent ubiquitin proteasome system activation plays an important role in high glucose- induced breast cancer cell growth and metastasis.


Subject(s)
Breast Neoplasms/drug therapy , Cell Movement/drug effects , Cell Proliferation/drug effects , Glucose/pharmacology , Proteasome Endopeptidase Complex/drug effects , Protein Kinase C-delta/metabolism , Ubiquitin/metabolism , Acetophenones/pharmacology , Apoptosis/drug effects , Benzopyrans/pharmacology , Boronic Acids/pharmacology , Bortezomib , Breast Neoplasms/metabolism , Cell Line, Tumor , Female , Glucose/metabolism , Humans , MCF-7 Cells , Phosphorylation/drug effects , Proteasome Inhibitors/pharmacology , Protein Kinase C-delta/antagonists & inhibitors , Pyrazines/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...